Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -28.57% and -43.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -28.57% and -43.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +56.67% and +116.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines (RVMD) delivered earnings and revenue surprises of +18.80% and +596.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?